Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

In Vivo CRISPR Gene Editing Market: LNP-Delivered Systemic Editing Demand, Base and Prime Editing Precision Growth, and Liver-Directed Therapeutic Application Adoption to Drive Steady Market Expansion Through 2036

The global In Vivo CRISPR Gene Editing Market is projected to expand at a steady CAGR of 15.2% through 2036, driven by sustained clinical demand for lipid nanoparticle-delivered systemic gene editing, growing development of base editing and prime editing technology offering improved precision over conventional double-strand-break editing, and continued concentration of therapeutic applications in liver-directed disease given favorable hepatic delivery characteristics. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises NTLA-2001 and other clinical-stage in vivo CRISPR editing candidates addressing transthyretin amyloidosis, hereditary angioedema, and other genetic diseases through direct systemic gene inactivation or correction. The market’s scope spans multiple grade tiers, formulation technologies, and distribution channels, reflecting the breadth of industrial, formulation, and specialty applications the category serves.

The market’s steady 15.2% CAGR reflects the continued clinical translation of CRISPR gene editing technology from ex vivo cell therapy applications into direct in vivo systemic administration, generating structured demand from specialized treatment centers well above discretionary specialty pharmaceutical demand growth. CRISPR-Cas9 continues to represent the most clinically advanced editing technology, while base editing and prime editing represent increasingly important precision editing alternatives designed to reduce off-target effects and unwanted insertions or deletions relative to conventional double-strand-break-inducing nuclease approaches. Coverage extending across multiple editing technologies, editing outcomes, and delivery platforms underscores the breadth of clinical infrastructure now supporting this maturing in vivo genetic medicine category.

Executive Snapshot

How does LNP-delivered systemic editing demand drive the in vivo CRISPR gene editing market?
Specialized treatment centers continue to administer lipid nanoparticle-delivered CRISPR-Cas9 candidates for systemic gene inactivation in conditions including transthyretin amyloidosis, establishing this delivery technology as a primary driver of current commercial and clinical activity. As additional LNP-delivered candidates continue to advance, procurement associated with this delivery platform is expected to remain a leading category through the forecast period. This trend has become increasingly pronounced over the past several reporting periods as end-use demand and regulatory priorities continue to evolve together. Analysts tracking this category note that procurement patterns have remained resilient even amid broader macroeconomic volatility.

What role does base and prime editing precision growth play in market expansion?
Biopharmaceutical developers continue to advance base editing and prime editing technology as more precise alternatives to conventional CRISPR-Cas9 double-strand-break editing, sustaining structured demand from developers pursuing these differentiated technologies given their potential for reduced off-target editing risk and more controlled genomic modification outcomes. Formulators and end users expect this pattern to persist through the remainder of the forecast period as underlying industrial and regulatory priorities remain in place. This has been corroborated by supplier commentary emphasizing continued order book strength across the recent reporting cycle.

How does liver-directed therapeutic application adoption sustain market growth?
Biopharmaceutical developers continue to concentrate in vivo CRISPR gene editing development on liver-directed diseases given favorable hepatic delivery characteristics for systemically administered lipid nanoparticles, sustaining structured demand from developers pursuing this established organ-targeting approach relative to more challenging extrahepatic delivery applications. This factor is widely viewed within the industry as one of the more durable structural drivers shaping procurement patterns across manufacturing and formulation accounts. Market participants describe this as one of the more predictable demand drivers within the broader chemical value chain.

What is driving demand for in vivo CRISPR editing in cardiovascular disease applications?
Developers pursuing in vivo CRISPR candidates for cardiovascular genetic disorders including elevated Lp(a) and PCSK9-associated hypercholesterolemia continue to extend this therapeutic modality beyond its historical rare disease core, generating incremental demand among clinical-stage biopharmaceutical developers pursuing these substantially larger addressable patient populations. This dynamic has been reinforced by broader shifts in how downstream manufacturers prioritize investment in next-generation formulation and process chemistry. Analysts tracking this category note that procurement patterns have remained resilient even amid broader macroeconomic volatility.

How does gene knockout and gene correction editing outcome demand sustain the market?
Biopharmaceutical developers continue to pursue both gene knockout, for conditions benefiting from gene inactivation, and gene correction, for conditions requiring precise mutation repair, sustaining structured demand from developers pursuing these differentiated editing outcome strategies depending on target disease biology. Analysts covering this specialty chemical sector expect this trend to remain a persistent feature of demand patterns through 2035. This has been corroborated by supplier commentary emphasizing continued order book strength across the recent reporting cycle.

Which in vivo CRISPR gene editing market segments are growing fastest?
The fastest-growing segments include base editing and prime editing technology, cardiovascular disease applications extending beyond rare genetic disorders, extrahepatic delivery technology development, and gene correction editing outcomes as the field matures beyond simpler gene knockout approaches. This factor is expected to remain relevant even as the broader industrial demand environment fluctuates over the coming decade. Market participants describe this as one of the more predictable demand drivers within the broader chemical value chain.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: In Vivo CRISPR Gene Editing Market

  • CRISPR-Cas9 sustaining the leading share of current clinical development activity among editing technologies: This editing technology continues to represent the most clinically advanced approach across current in vivo gene editing candidates. This pattern is consistent with broader trends observed across adjacent specialty and industrial chemical categories.
  • Lipid nanoparticle delivery sustaining the dominant delivery platform for current systemic in vivo editing applications: This delivery technology continues to anchor the substantial majority of current in vivo CRISPR gene editing clinical activity. Suppliers with technical depth and established customer relationships are generally best positioned to capture this structural advantage.
  • Liver-directed applications sustaining the leading therapeutic target organ given favorable delivery characteristics: Hepatic targeting continues to represent the most clinically validated organ system for systemic lipid nanoparticle-delivered gene editing. This dynamic is expected to persist as downstream applications continue to mature and expand into new end-use categories.
  • Base editing and prime editing sustaining structured demand growth as increasingly important precision alternatives: These technologies continue to attract developer investment pursuing reduced off-target editing risk relative to conventional nuclease-based approaches. Industry participants view this as one of the more stable structural features of the category’s demand base.
  • Gene knockout sustaining the leading editing outcome across current commercial and clinical-stage candidates: This outcome continues to represent the most clinically validated editing approach given its relative technical simplicity relative to gene correction or insertion. This trend has held steady across recent reporting periods and shows limited signs of reversal.
  • Cardiovascular disease applications sustaining structured demand growth beyond the field’s historical rare disease core: This therapeutic area continues to broaden the category’s overall addressable patient population given substantial cardiovascular disease prevalence. Suppliers able to adapt to this dynamic are generally sustaining stronger customer retention outcomes.

Market Segmentation: In Vivo CRISPR Gene Editing Market

By Editing Technology
  • CRISPR-Cas9
  • CRISPR-Cas12
  • CRISPR-Cas13
  • Base Editing
  • Prime Editing
  • Other CRISPR-Based Editing Technologies
By Editing Outcome
  • Gene Knockout
  • Gene Correction
  • Gene Insertion
  • Gene Replacement
  • Gene Activation
  • Gene Repression
  • Base Conversion
  • Other Editing Outcomes
By Delivery System
  • Viral Vectors
    • AAV
    • Lentiviral vectors
    • Adenoviral vectors
    • Other viral vectors
  • Non-Viral Delivery
    • Lipid nanoparticles (LNPs)
    • Polymer-based nanoparticles
    • Liposomes
    • Other non-viral systems
By Route of Administration
  • Intravenous
  • Intramuscular
  • Intrathecal
  • Intracerebroventricular
  • Intracerebral/Intraparenchymal
  • Subretinal
  • Intravitreal
  • Intranasal
  • Other Routes
By CRISPR Payload
  • Cas Nuclease + Guide RNA
  • mRNA + Guide RNA
  • DNA-Based CRISPR Components
  • Ribonucleoprotein (RNP)
  • Base Editor Systems
  • Prime Editor Systems
  • Other CRISPR Payloads
By Target Tissue
  • Liver
  • Central Nervous System
  • Skeletal Muscle
  • Cardiovascular System
  • Eye/Retina
  • Lung
  • Kidney
  • Pancreas
  • Other Target Tissues
By Application
  • Genetic Disorders
  • Cardiovascular Diseases
  • Neurological Disorders
  • Oncology
  • Metabolic Disorders
  • Ophthalmic Disorders
  • Infectious Diseases
  • Other Applications
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Biopharmaceutical Companies
  • Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Other End Users
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: In Vivo CRISPR Gene Editing Market

  1. Sustained clinical progress of lipid nanoparticle-delivered candidates driving continued systemic editing investment: This delivery platform continues to support structured demand above the discretionary specialty pharmaceutical baseline. This driver is expected to remain structurally significant through the full forecast horizon. Suppliers with diversified regional production footprints are generally best positioned to capture this incremental demand.
  2. Growing developer investment in base and prime editing technology supporting improved precision and safety profiles: These technologies continue to attract structured research investment pursuing reduced off-target editing risk. Suppliers investing ahead of this trend are generally capturing disproportionate customer retention benefits. This driver has shown consistent resilience across multiple recent reporting cycles.
  3. Continued concentration on liver-directed applications supporting near-term clinical translation: Favorable hepatic delivery characteristics continue to attract structured developer investment given established technical feasibility. This factor complements several of the other structural drivers shaping the category’s growth trajectory. Suppliers with diversified regional production footprints are generally best positioned to capture this incremental demand.
  4. Sustained extension into cardiovascular disease broadening the addressable therapeutic market: This therapeutic area continues to generate incremental demand among clinical-stage biopharmaceutical developers pursuing larger patient populations. Industry participants broadly expect this driver to sustain its relevance through 2035. This driver has shown consistent resilience across multiple recent reporting cycles.
  5. Growing research investment in extrahepatic delivery technology supporting future application diversification: Continued technology development continues to focus industry attention on expanding beyond liver-directed applications. This trend is reinforced by parallel developments across adjacent end-use and regulatory categories. Suppliers with diversified regional production footprints are generally best positioned to capture this incremental demand.
  6. Maturing clinical pipeline supporting an approaching wave of additional in vivo gene editing approvals: A growing number of Phase II and Phase III candidates continues to focus treatment center and payer attention on the category’s next phase of expansion. Continued investment against this driver is expected from both established and emerging suppliers alike. This driver has shown consistent resilience across multiple recent reporting cycles.

Regional Outlook: In Vivo CRISPR Gene Editing Market

  • North America: The United States accounts for the largest share of regional demand, supported by extensive specialized treatment center infrastructure and leading clinical trial activity in in vivo gene editing development.
  • Europe: Germany, the United Kingdom, and Switzerland anchor regional demand, supported by growing specialized treatment center capacity and consistent multinational clinical trial participation.
  • Asia-Pacific: China, Japan, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers expand their own in vivo gene editing pipelines.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized treatment centers begin to participate in in vivo gene editing clinical trials.

Competitive Landscape: In Vivo CRISPR Gene Editing Market

Key Players
Intellia Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Beam Therapeutics Inc., Verve Therapeutics, Inc., Prime Medicine, Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Metagenomi, Inc., Arbor Biotechnologies, Inc., Wave Life Sciences Ltd., Precision BioSciences, Inc., Graphite Bio, Inc., Chroma Medicine, Inc., Tenaya Therapeutics, Inc.

  • Intellia Therapeutics, Inc. [March 2026] — confirmed continued Phase 3 clinical development of its in vivo CRISPR editing candidate for transthyretin amyloid cardiomyopathy, with the company noting sustained investigator interest in its single-infusion approach.
  • Verve Therapeutics, Inc. [December 2025] — reported continued clinical progress for its in vivo base editing candidate targeting PCSK9 for cardiovascular risk reduction, with the company noting sustained interest in extending gene editing into broader cardiovascular disease populations.
  • Beam Therapeutics Inc. [September 2025] — confirmed continued clinical development of its base editing pipeline, with the company reporting structured investor interest in extending its precision editing platform to additional liver-directed and extrahepatic applications.

Consultant POV

The In Vivo CRISPR Gene Editing Market’s steady 15.2% CAGR outlook through 2036 is anchored in sustained LNP-delivered systemic editing demand, growing base and prime editing precision activity, and continued liver-directed therapeutic application adoption. Sustained clinical and manufacturing investment from companies including Intellia Therapeutics, Inc., Verve Therapeutics, Inc., and Beam Therapeutics Inc. confirms the In Vivo CRISPR Gene Editing Market will sustain steady growth through 2036.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report